MediciNova sinks after meth dependence failure

MediciNova Inc. (NASDAQ:MNOV; JASDAQ:4875) lost $1.74 (15%) to $10.22 on NASDAQ Thursday after reporting that ibudilast (MN-166) missed the primary endpoint of improving methamphetamine abstinence compared with placebo in a Phase II trial to treat

Read the full 354 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE